Biodexa Reports Favorable Phase I DMG Trial Outcomes and R&D Progress

Biodexa Pharmaceuticals PLC, a biopharmaceutical firm listed on NASDAQ as BDRX, has reported encouraging preliminary results from a Phase I clinical trial for MTX110, a treatment for diffuse midline glioma (DMG), a type of brain cancer. The study, conducted by Columbia University Irving Medical Center, utilized a novel convection enhanced delivery method directly to the pons region of the brain. The trial's primary focus was on safety and tolerability, with a limited number of infusions. Despite not being designed to measure efficacy, the median overall survival of patients was 16.5 months, which is significantly higher than the 10.0 months median survival observed in a comparable group of 316 cases.
The company also disclosed that an in vitro experiment to assess the potential of tolimidone, another drug in development for type 1 diabetes, to stimulate beta cell proliferation was inconclusive. However, Biodexa remains committed to further in vivo preclinical studies and is preparing for a Phase IIa clinical trial for tolimidone in patients with type 1 diabetes, expected to commence later this year.
Biodexa is advancing a pipeline of innovative treatments for diseases with significant medical needs, including type 1 diabetes and rare brain cancers. Their lead programs feature tolimidone, an inhibitor of lyn kinase with potential as a novel treatment for diabetes, and MTX110, a solubilized formulation of the HDAC inhibitor panobinostat, which is being studied for its application in aggressive brain cancers. The company is headquartered in Cardiff, UK, and is supported by proprietary drug delivery technologies aimed at enhancing the bioavailability and distribution of medicines.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!